447 related articles for article (PubMed ID: 22192660)
21. Cytokines in the pathogenesis of systemic lupus erythematosus.
Kelley VR; Wüthrich RP
Semin Nephrol; 1999 Jan; 19(1):57-66. PubMed ID: 9952281
[TBL] [Abstract][Full Text] [Related]
22. Effect of Autoantibodies to Erythropoietin Receptor in Systemic Lupus Erythematosus with Biopsy-proven Lupus Nephritis.
Hara A; Furuichi K; Yamahana J; Yasuda H; Iwata Y; Sakai N; Shimizu M; Kaneko S; Wada T
J Rheumatol; 2016 Jul; 43(7):1328-34. PubMed ID: 27134248
[TBL] [Abstract][Full Text] [Related]
23. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis.
Ramanujam M; Steffgen J; Visvanathan S; Mohan C; Fine JS; Putterman C
Autoimmun Rev; 2020 Nov; 19(11):102668. PubMed ID: 32942031
[TBL] [Abstract][Full Text] [Related]
24. Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis.
Kanapathippillai P; Hedberg A; Fenton CG; Fenton KA
Cytokine; 2013 May; 62(2):244-52. PubMed ID: 23561928
[TBL] [Abstract][Full Text] [Related]
25. Rapamycin alleviates renal damage in mice with systemic lupus erythematosus through improving immune response and function.
Song X; Gao J; Liu H; Liu X; Tang K
Biomed Pharmacother; 2021 May; 137():111289. PubMed ID: 33581650
[TBL] [Abstract][Full Text] [Related]
26. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
[TBL] [Abstract][Full Text] [Related]
27. Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.
Urbonaviciute V; Starke C; Pirschel W; Pohle S; Frey S; Daniel C; Amann K; Schett G; Herrmann M; Voll RE
Arthritis Rheum; 2013 Jun; 65(6):1612-23. PubMed ID: 23450347
[TBL] [Abstract][Full Text] [Related]
28. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis.
Moreth K; Brodbeck R; Babelova A; Gretz N; Spieker T; Zeng-Brouwers J; Pfeilschifter J; Young MF; Schaefer RM; Schaefer L
J Clin Invest; 2010 Dec; 120(12):4251-72. PubMed ID: 21084753
[TBL] [Abstract][Full Text] [Related]
29. Role of lipids in the progression of renal disease in systemic lupus erythematosus patients.
Luzar B; Ferluga D
Wien Klin Wochenschr; 2000 Aug; 112(15-16):716-21. PubMed ID: 11020963
[TBL] [Abstract][Full Text] [Related]
30. Autoantibodies as markers for detecting concurrent disease activity in systemic lupus erythematosus.
Ntali S; Karim MY
Transl Res; 2010 Dec; 156(6):317-9. PubMed ID: 21078492
[No Abstract] [Full Text] [Related]
31. Th1/Th2 balance of SLE patients with lupus nephritis.
Nakashima H; Akahoshi M; Masutani K
Rinsho Byori; 2006 Jul; 54(7):706-13. PubMed ID: 16913661
[TBL] [Abstract][Full Text] [Related]
32. Anti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation.
Bethunaickan R; Sahu R; Liu Z; Tang YT; Huang W; Edegbe O; Tao H; Ramanujam M; Madaio MP; Davidson A
Arthritis Rheum; 2012 Oct; 64(10):3399-408. PubMed ID: 22674120
[TBL] [Abstract][Full Text] [Related]
33. Comparison of urinary parameters, biomarkers, and outcome of childhood systemic lupus erythematosus early onset-lupus nephritis.
Miguel DF; Terreri MT; Pereira RMR; Bonfá E; Silva CAA; Corrente JE; Magalhaes CS;
Adv Rheumatol; 2020 Feb; 60(1):10. PubMed ID: 32005292
[TBL] [Abstract][Full Text] [Related]
34. Genetics of Lupus Nephritis: Clinical Implications.
Munroe ME; James JA
Semin Nephrol; 2015 Sep; 35(5):396-409. PubMed ID: 26573543
[TBL] [Abstract][Full Text] [Related]
35. Anti-TLR7 Antibody Protects Against Lupus Nephritis in NZBWF1 Mice by Targeting B Cells and Patrolling Monocytes.
Murakami Y; Fukui R; Tanaka R; Motoi Y; Kanno A; Sato R; Yamaguchi K; Amano H; Furukawa Y; Suzuki H; Suzuki Y; Tamura N; Yamashita N; Miyake K
Front Immunol; 2021; 12():777197. PubMed ID: 34868046
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis.
Halfon M; Tankeu AT; Ribi C
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892349
[TBL] [Abstract][Full Text] [Related]
37. The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis.
Adhya Z; Borozdenkova S; Karim MY
Nephrol Dial Transplant; 2011 Oct; 26(10):3273-80. PubMed ID: 21372259
[TBL] [Abstract][Full Text] [Related]
38. Basophils and the T helper 2 environment can promote the development of lupus nephritis.
Charles N; Hardwick D; Daugas E; Illei GG; Rivera J
Nat Med; 2010 Jun; 16(6):701-7. PubMed ID: 20512127
[TBL] [Abstract][Full Text] [Related]
39. GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of Lupus.
Nataraja C; Dankers W; Flynn J; Lee JPW; Zhu W; Vincent FB; Gearing LJ; Ooi J; Pervin M; Cristofaro MA; Sherlock R; Hasnat MA; Harris J; Morand EF; Jones SA
Front Immunol; 2021; 12():652800. PubMed ID: 33889157
[TBL] [Abstract][Full Text] [Related]
40. Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation.
Marczynski P; Meineck M; Xia N; Li H; Kraus D; Roth W; Möckel T; Boedecker S; Schwarting A; Weinmann-Menke J
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
